glp 1 agonist dementia Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment Adults whose type 2 diabetes

Pratley R, Nauck M, Bailey T, et al

Personality features in obesity

391 GLP-1 and GLP-1 analogs exert their effects on food intake and body weight through a myriad of neural substrates, encompassing several hypothalamic nuclei (including the arcuate nucleus of the hypothalamus, periventricular hypothalamus, and lateral hypothalamic area), hindbrain nuclei (such as the parabrachial nucleus and medial nucleus tractus solitarius), the ventral subregion of the hippocampus (vHP), and nuclei embedded within the mesolimbic reward circuitry (including the ventral tegmental area, VTA, and nucleus accumbens, NAc)

The myriad of effects of endogenous glucagon-like peptide-1 (GLP-1) make it an attractive target for diabetes therapy

The possibility of providing preventive regimen in multi system pathologies is a significant use of the GLP-1RA in improving disease outcomes and preventing morbidity

Drug Type Segment Insights and Analysis: Based on the drug type, the GLP-1 Receptor Agonist market is segmented into Short-Acting GLP-1 and Long-Acting GLP-1